Search
Prednylidene
go.drugbank.com/drugs/DB13208ExperimentalPrednylidene is an experimental systemic glucocorticoid.
Tetramisole
go.drugbank.com/drugs/DB16561InvestigationalTetramisole is an anthelmintic agent.[A275223]
Pegzilarginase
go.drugbank.com/drugs/DB14780ApprovedPegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).
Dextrothyroxine
go.drugbank.com/drugs/DB00509ApprovedWithdrawnThyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism.
GI-4000
go.drugbank.com/drugs/DB05698InvestigationalA vaccine containing a heat-killed recombinant <em>Saccharomyces cerevisiae</em> yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant
Sitamaquine
go.drugbank.com/drugs/DB04909InvestigationalSitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential
Ispectamab debotansine
go.drugbank.com/drugs/DB18456InvestigationalIspectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid
LMB-100
go.drugbank.com/drugs/DB18591InvestigationalLMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.
Human varicella-zoster immune globulin
go.drugbank.com/drugs/DB11621ApprovedInvestigationalHuman varicella-zoster immune globulin is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). … It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the disease severity in high-risk patients who